Key result
Hybrid closed-loop systems are associated with significant improvements in glycaemic control and provide important quality of life benefits for users with Type 1 Diabetes Mellitus and their families.
Why the study?
Hybrid closed-loop systems are transforming clinical management of T1DM with emerging evidence on safety, efficacy, and psychosocial benefits, requiring synthesis of current data and future challenges.
Hybrid closed-loop systems provide significant improvements in glycaemic control and quality of life for patients with T1DM, though equitable access and healthcare professional readiness remain challenges in the UK.
May support hybrid closed-loop adoption in T1DM where approved; leaves open long-term equity and implementation questions.
Hybrid closed-loop systems are transforming the clinical management of T1DM. Large randomised controlled trials of hybrid closed-loop systems have demonstrated safety and efficacy, with significant improvements in glycaemic control compared to control therapy, and there are now several commercially approved hybrid closed-loop systems available in the UK. There is also a growing body of evidence demonstrating the quality of life benefits associated with hybrid closed-loop systems, both for users and also for parents/caregivers and other family members. We review the clinical evidence supporting currently available hybrid closed-loop systems in the UK and also new systems on the horizon. We discuss the emerging evidence for associated psychosocial benefits of hybrid closed-loop therapy. We also address future challenges around healthcare professional readiness to deliver closed-loop technology and ensuring equitable access across the UK.
No takes yet. Share an insight, caveat, or question.
Boughton et al. (2022) conducted a review in Type 1 Diabetes Mellitus. Hybrid closed-loop systems vs. Control therapy (sensor-augmented pump therapy or usual care) was evaluated. Hybrid closed-loop systems are associated with significant improvements in glycaemic control and provide important quality of life benefits for users with Type 1 Diabetes Mellitus and their families.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: